Policy / Pricing A ‘hijacked plane’: CDC, under RFK Jr.’s influence, trades science for dogma BioPharma DiveA series of controversial policy changes directed by the HHS secretary have left experts fearful of the future implications for public health.Policy / PricingRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) BioPharma Dive A series of controversial policy changes directed by the HHS secretary have left experts fearful of the future implications for public health. Policy / PricingRead full story Post navigation Previous: Agios mulls early FDA filing for sickle cell therapyNext: FDA, after turbulent year, leaves drugmakers guessing on its direction Related Stories Policy / Pricing MFN affecting Swiss medicines access, says Interpharma pharminent August 13, 2026 Policy / Pricing Prior Authorization Metrics Provide New Insights into Insurer Practices, but Gaps Remain pharminent August 13, 2026 Policy / Pricing Trump signs order that nearly halves childhood immunisation coverage pharminent August 11, 2026
